United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Robo.ai ( NASDAQ:AIIO ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Tuesday. Shares of United Natural Foods, Inc. ( NYSE:UNFI ) rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter EPS and sales and issued FY26 EPS guidance above ...
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Are Medical Stocks Lagging Adaptive Biotechnologies ( ADPT ) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Is Cardinal Health ( CAH ) Stock Outpacing Its Medical Peers This Year?
Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies ( ADPT ) is a Great Choice
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Adaptive Biotechnologies Corporation ( ADPT ) Hits Fresh High: Is There Still Room to Run?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Adaptive Biotechnologies ( ADPT ) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation ( ADPT ) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Adaptive Biotechnologies ( ADPT ) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cathie Wood Scoops Up $38 Million Worth Of AMD Stock As It Slips - Dumps Palantir And Shopify At Highs - ARK Fintech Innovation ETF ( BATS:ARKF ) , Advanced Micro Devices ( NASDAQ:AMD )
On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Advanced Micro Devices Inc. AMD, Palantir Technologies Inc. PLTR, and Shopify Inc. SHOP. These trades reflect Ark's strategic adjustments in response to recent market developments and earnings reports.
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
One of the company's businesses is particularly hot at the moment.
Adaptive ( ADPT ) Q2 Revenue Surges 36%
Adaptive Biotechnologies ( NASDAQ:ADPT ) , a company specializing in immune-driven clinical diagnostics and therapeutics, posted its second quarter fiscal 2025 earnings on August 5, 2025. The report revealed a significant jump in revenue to $58.9 million ( GAAP ) , beating analyst expectations of ...
Adaptive Biotechnologies ( ADPT ) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna ( MRNA ) Reports Q2 Loss, Beats Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +28.76% and +11.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Adaptive Biotechnologies ( ADPT ) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Cathie Wood Doubles Down On Tesla Amid Elon Musk's Feud With Trump, Sells $3 Million Worth Of Coinbase Stock - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Tesla Inc. and Coinbase Global Inc. . These trades reflect Ark's strategic positioning amid ongoing market developments. The transactions occurred as Tesla faced a dip in share price due to external factors, while Coinbase ...
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.
Adaptive Biotechnologies ( ADPT ) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes Adaptive Biotechnologies ( ADPT ) a New Buy Stock
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Adaptive Biotechnologies ( ADPT ) Stock Outpacing Its Medical Peers This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Cathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground - Ark Dumps Palantir Amid Privacy Concerns - ARK Innovation ETF ( BATS:ARKK ) , Palantir Technologies ( NASDAQ:PLTR )
On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Tesla Inc. TSLA and Palantir Technologies Inc. PLTR. The Tesla Trade: Ark Invest sold 1,594 shares of the Elon Musk-led company.
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - Adaptive Biotechnologies ( NASDAQ:ADPT )
SEATTLE, May 30, 2025 ( GLOBE NEWSWIRE ) -- Adaptive Biotechnologies Corporation ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation ...
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers 30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers ...
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
Is First Trust Small Cap Growth AlphaDEX ETF ( FYC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Cathie Wood Ditches $5.6M More Tesla While Elon Musk Quits Government Role - Doubles Down On AI Stock Under Attack By Short Sellers - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )
On Wednesday, Cathie Wood's Ark Invest made notable trades involving Tesla Inc. and Tempus AI Inc. . These trades come amid significant developments for both companies, with Tesla's insider sales raising eyebrows and Tempus AI facing scrutiny from short sellers.
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 ( GLOBE NEWSWIRE ) -- Adaptive Biotechnologies Corporation ( Nasdaq: ADPT ) , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be ...
Is Adaptive Biotechnologies ( ADPT ) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Should First Trust Small Cap Growth AlphaDEX ETF ( FYC ) Be on Your Investing Radar?
Style Box ETF report for ...
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Adaptive Biotechnologies ( ADPT ) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Cathie Wood's $21.5 Million Shopify Grab Defies Post-Earnings Dip, Ark Continues Dumping Palantir, Also Chops Jack Dorsey's Block - ARK Fintech Innovation ETF ( BATS:ARKF )
On Thursday, Cathie Wood-led Ark Invest made significant moves in the stock market, focusing on Shopify Inc. SHOP, Palantir Technologies Inc. PLTR, and Block Inc. XYZ.
Does Adaptive Biotechnologies ( ADPT ) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Adaptive Biotechnologies ( ADPT ) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results - Apple ( NASDAQ:AAPL ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 300 points on Friday. The Dow traded up 1.43% to 41,337.37 while the NASDAQ climbed 1.76% to 18,023.33. The S&P 500 also rose, gaining, 1.61% to 5,694.47. Communication services shares jumped by 2.7% ...
